[Alpha Tau in PR Newswire] Alpha Tau announces completion of enrollment of Japanese pivotal clinical trial in recurrent head & neck cancer
Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its clinical trial partner in Japan, that recruitment has been completed in its open-label multi-center pivotal study evaluating the Alpha DaRT in Japanese patients with recurrent Head & Neck cancer after radiotherapy. Read more...
Read More